estazolam ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
diazepam derivatives 1056 29975-16-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • estazolam
  • tasedan
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.
  • Molecular weight: 294.74
  • Formula: C16H11ClN4
  • CLOGP: 2.29
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 43.07
  • ALOGS: -3.84
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 4 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.10 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 26, 1990 FDA ABBOTT

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Serotonin syndrome 54.58 24.29 25 2203 24688 50578208
Electrocardiogram QT prolonged 47.14 24.29 29 2199 51857 50551039
Intentional overdose 39.85 24.29 28 2200 62476 50540420
Disseminated intravascular coagulation 36.77 24.29 17 2211 17118 50585778
Drug interaction 35.94 24.29 44 2184 199577 50403319
Ventricular arrhythmia 32.46 24.29 10 2218 3299 50599597
Electrocardiogram QRS complex prolonged 31.56 24.29 11 2217 5333 50597563
Bradycardia 30.19 24.29 24 2204 64402 50538494
Suicide attempt 28.01 24.29 21 2207 51711 50551185
Rhabdomyolysis 26.06 24.29 18 2210 39009 50563887
Poverty of speech 24.36 24.29 5 2223 316 50602580

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hyperammonaemia 30.79 23.02 11 1310 5652 29567554
Inappropriate antidiuretic hormone secretion 30.21 23.02 13 1308 10919 29562287
Altered state of consciousness 28.36 23.02 15 1306 19874 29553332
Delirium 28.08 23.02 19 1302 39378 29533828

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Delirium 45.68 20.75 35 3619 69159 64425919
Drug interaction 40.56 20.75 73 3581 362010 64133068
Electrocardiogram QT prolonged 37.36 20.75 33 3621 79415 64415663
Altered state of consciousness 36.15 20.75 24 3630 37878 64457200
Intentional overdose 35.74 20.75 34 3620 89910 64405168
Persecutory delusion 31.53 20.75 11 3643 4147 64490931
Serotonin syndrome 30.68 20.75 22 3632 39260 64455818
Rhabdomyolysis 29.65 20.75 31 3623 91695 64403383
Inappropriate antidiuretic hormone secretion 28.50 20.75 17 3637 22272 64472806
Suicide attempt 26.61 20.75 26 3628 70981 64424097
Disseminated intravascular coagulation 24.99 20.75 18 3636 32330 64462748
Hepatic function abnormal 23.07 20.75 23 3631 64290 64430788
Electrocardiogram QRS complex prolonged 23.03 20.75 11 3643 9233 64485845
Hyperammonaemia 22.31 20.75 11 3643 9893 64485185
Ventricular arrhythmia 22.13 20.75 10 3644 7405 64487673
Neuroleptic malignant syndrome 21.84 20.75 15 3639 24981 64470097

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05CD04 NERVOUS SYSTEM
PSYCHOLEPTICS
HYPNOTICS AND SEDATIVES
Benzodiazepine derivatives
FDA CS M0002356 Benzodiazepines
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:50268 GABA modulators
MeSH PA D014151 Anti-Anxiety Agents
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D018682 GABA Agents
MeSH PA D018757 GABA Modulators
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
FDA EPC N0000175694 Benzodiazepine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Severe Insomnia indication
Alcohol intoxication contraindication 25702006
Depressive disorder contraindication 35489007
Substance abuse contraindication 66214007
Psychotic disorder contraindication 69322001
Sleep apnea contraindication 73430006 DOID:0050847
Kidney disease contraindication 90708001 DOID:557
Myasthenia gravis contraindication 91637004 DOID:437
Disease of liver contraindication 235856003 DOID:409
Pregnancy, function contraindication 289908002
Severe chronic obstructive pulmonary disease contraindication 313299006
Breastfeeding (mother) contraindication 413712001




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.82 Basic
pKa2 4.83 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
GABA-A receptor alpha-1/beta-2/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-2/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-3/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL
GABA-A receptor alpha-5/beta-3/gamma-2 Ion channel POSITIVE ALLOSTERIC MODULATOR WOMBAT-PK CHEMBL

External reference:

IDSource
4019566 VUID
N0000147666 NUI
D00311 KEGG_DRUG
4019566 VANDF
C0014892 UMLSCUI
CHEBI:4858 CHEBI
CHEMBL285674 ChEMBL_ID
DB01215 DRUGBANK_ID
D004949 MESH_DESCRIPTOR_UI
3261 PUBCHEM_CID
7550 IUPHAR_LIGAND_ID
3611 INN_ID
36S3EQV54C UNII
4077 RXNORM
10202 MMSL
4682 MMSL
d00915 MMSL
003566 NDDF
371364001 SNOMEDCT_US
96235001 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 0591-0744 TABLET 1 mg ORAL ANDA 16 sections
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 0591-0745 TABLET 2 mg ORAL ANDA 16 sections
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 21695-220 TABLET 2 mg ORAL ANDA 29 sections
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 51862-069 TABLET 1 mg ORAL ANDA 33 sections
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 51862-070 TABLET 2 mg ORAL ANDA 33 sections
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 51862-073 TABLET 1 mg ORAL ANDA 33 sections
Estazolam HUMAN PRESCRIPTION DRUG LABEL 1 51862-074 TABLET 2 mg ORAL ANDA 33 sections
Estazolam Human Prescription Drug Label 1 70954-480 TABLET 1 mg ORAL ANDA 27 sections
Estazolam Human Prescription Drug Label 1 70954-481 TABLET 2 mg ORAL ANDA 27 sections